High-dose vitamin C as a targeted treatment for KRAS-driven cancers?
KRAS mutations are frequently observed in human cancer and are associated with proliferation, therapy-resistance and worse outcome. Regrettably, only a fraction of possible mutations is druggable. Therefore, a tailored and possibly cost-effective method to overcome this issue is urgently needed.Rece...
Saved in:
| Main Authors: | Elisabeth Mack, Christian Rau, Cornelia Otet, Jonas Aaron Schäfer, Cornelia Brendel, Albert Grass, Peer Bredow, Christian Hohl, Carsten Denkert, Frank Willeke, Andreas Neubauer |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-09-01
|
| Series: | Redox Biology |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2213231725002393 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
SELECTIVE INHIBITION OF KRAS SIGNALING BY COMBINATION OF LOW DOSE RAPAMYCIN AND PACLITAXEL IN VIVO
by: M. N. Yurova, et al.
Published: (2018-07-01) -
KRAS Mutation Status in Relation to Clinicopathological Characteristics of Romanian Colorectal Cancer Patients
by: Elena-Roxana Avădănei, et al.
Published: (2025-02-01) -
Marijan Kraš
by: Andrea Toljan, et al.
Published: (2023-11-01) -
Reverse engineering a hierarchical regulatory network downstream of oncogenic KRAS
by: Iwona Stelniec‐Klotz, et al.
Published: (2012-07-01) -
Targeting KRAS‐mutant pancreatic cancer through simultaneous inhibition of KRAS, MEK, and JAK2
by: Satoru Miyazaki, et al.
Published: (2025-02-01)